drugset / Trial / NCT00556075

Safety and Efficacy Study to Evaluate Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis

NCT00556075

Phase 2 Terminated 67 enrolled Repros Therapeutics Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine whether Proellex is safe and effective for the treatment of symptomatic endometriosis.

Timeline

Start
2007-11
Primary completion
2009-05
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Telapristone Acetate Other / unclassified 25 mg
Subject Telapristone Acetate Other / unclassified 50 mg

Indications